BR112012015202A2 - "iota - e/ou kappa-carrgenado junto com um inibidor da neuraminidase, método para o tratamento profilático ou terapêutico de um sintoma, condição ou doença, composição farmacêutica,e, kit de partes". - Google Patents

"iota - e/ou kappa-carrgenado junto com um inibidor da neuraminidase, método para o tratamento profilático ou terapêutico de um sintoma, condição ou doença, composição farmacêutica,e, kit de partes".

Info

Publication number
BR112012015202A2
BR112012015202A2 BR112012015202A BR112012015202A BR112012015202A2 BR 112012015202 A2 BR112012015202 A2 BR 112012015202A2 BR 112012015202 A BR112012015202 A BR 112012015202A BR 112012015202 A BR112012015202 A BR 112012015202A BR 112012015202 A2 BR112012015202 A2 BR 112012015202A2
Authority
BR
Brazil
Prior art keywords
iota
kappa
prophylactic
symptom
condition
Prior art date
Application number
BR112012015202A
Other languages
English (en)
Other versions
BR112012015202B1 (pt
Inventor
Andreas Grassauer
Christiane Meier
Eva Prieschl-Grassauer
Marielle König-Schuster
Original Assignee
Marinomed Biotechnologie Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44063696&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012015202(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Marinomed Biotechnologie Gmbh filed Critical Marinomed Biotechnologie Gmbh
Publication of BR112012015202A2 publication Critical patent/BR112012015202A2/pt
Publication of BR112012015202B1 publication Critical patent/BR112012015202B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/731—Carrageenans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

"iotas-e/ou kappa-caragenado junto com um inibidor da neuraminidase, método para o tratamento profilático ou terapêutico de um sintoma, condição ou doença, composição farmacêutica,e, kit de partes". a presente invenção diz respeito a iota- e/ou kappa-cazrregenano em combinação com um inibidor da neuraminidase para uso como um medicamento no tratamento profilático ou terapêutico de um sintoma, condição ou doença causado ou associado com uma infecção por um vírus influenza.
BR112012015202-5A 2009-12-22 2010-12-17 uso de iota- e/ou kappa-carragenano junto com um inibidor da neuraminidase, e, composição farmacêutica BR112012015202B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28214809P 2009-12-22 2009-12-22
US61/282,148 2009-12-22
PCT/EP2010/007726 WO2011076367A2 (en) 2009-12-22 2010-12-17 Synergistic antiviral composition and use thereof

Publications (2)

Publication Number Publication Date
BR112012015202A2 true BR112012015202A2 (pt) 2016-04-05
BR112012015202B1 BR112012015202B1 (pt) 2020-12-08

Family

ID=44063696

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012015202-5A BR112012015202B1 (pt) 2009-12-22 2010-12-17 uso de iota- e/ou kappa-carragenano junto com um inibidor da neuraminidase, e, composição farmacêutica

Country Status (21)

Country Link
US (1) US10022449B2 (pt)
EP (1) EP2515889B1 (pt)
JP (1) JP5902628B2 (pt)
KR (1) KR101862415B1 (pt)
CN (1) CN102652017A (pt)
AU (1) AU2010335594B2 (pt)
BR (1) BR112012015202B1 (pt)
CA (1) CA2779532C (pt)
CL (1) CL2012001695A1 (pt)
DK (1) DK2515889T3 (pt)
EA (1) EA022840B1 (pt)
ES (1) ES2531367T3 (pt)
IL (1) IL219552A (pt)
MX (1) MX2012007166A (pt)
NZ (1) NZ599839A (pt)
PL (1) PL2515889T3 (pt)
PT (1) PT2515889E (pt)
SG (1) SG181421A1 (pt)
SI (1) SI2515889T1 (pt)
WO (1) WO2011076367A2 (pt)
ZA (1) ZA201202482B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012126777A1 (en) * 2011-03-18 2012-09-27 Marinomed Biotechnologie Gmbh Inhibition of neuraminidase activity
RU2469020C1 (ru) * 2011-11-08 2012-12-10 Александр Васильевич Иващенко (3r,4r,5s)-5-амино-4-ациламино-3-(1-этил-пропокси)-циклогекс-1-ен-карбоновые кислоты, их эфиры и способ применения
RU2520836C1 (ru) * 2013-02-27 2014-06-27 Александр Васильевич Иващенко (3r,4r,5s)-4-амино-5-(2,2-дифторацетиламино)-3-(1-этилпропокси)-циклогекс-1-енкарбоновая кислота и ее эфиры, способ их получения и применения
PT2898888T (pt) * 2014-01-22 2019-07-16 Visufarma B V Composição que compreende iota-carragenina contra conjuntivite viral
US20170246262A1 (en) * 2016-02-25 2017-08-31 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants
EP3691672A1 (en) * 2017-10-06 2020-08-12 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd Peptides for use in the treatment of viral infections
WO2019160261A1 (ko) * 2018-02-14 2019-08-22 (주)나노메디카 항바이러스 처리 방법, 항바이러스 필터, 및 이를 구비한 마스크
KR102316819B1 (ko) * 2018-04-20 2021-10-25 한미약품 주식회사 카라기난을 유효성분으로 포함하는 보존성이 개선된 액상 제제
JPWO2021002355A1 (pt) * 2019-07-03 2021-01-07
CN116209435A (zh) * 2020-03-18 2023-06-02 因斯特科技公司 用于治疗冠状病毒感染和呼吸功能损伤的组合物和方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593314B1 (en) * 1999-10-19 2003-07-15 Abbott Laboratories Neuraminidase inhibitors
JP2001181188A (ja) * 1999-12-28 2001-07-03 Marine Biotechnol Inst Co Ltd インフルエンザウイルス感染阻害剤
EP1930015A1 (en) * 2006-12-05 2008-06-11 Marinomed Biotechnologie GmbH Use of carrageenan for treating rhinovirus infections
JP5470047B2 (ja) 2006-12-05 2014-04-16 マリノメド バイオテクノロジー ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ウイルス組成物及び使用方法
CA2673313A1 (en) * 2006-12-18 2008-12-04 Amcol International Virus-interacting layered phyllosilicates and methods of use
CN101784272B (zh) * 2007-08-24 2014-03-12 玛丽诺姆德生物技术公司 包含硫酸多糖的抗病毒组合物

Also Published As

Publication number Publication date
EP2515889B1 (en) 2014-12-10
EA022840B1 (ru) 2016-03-31
EP2515889A2 (en) 2012-10-31
PL2515889T3 (pl) 2015-05-29
ES2531367T3 (es) 2015-03-13
CL2012001695A1 (es) 2013-03-08
SG181421A1 (en) 2012-07-30
JP5902628B2 (ja) 2016-04-13
AU2010335594A1 (en) 2012-05-24
CA2779532A1 (en) 2011-06-30
IL219552A0 (en) 2012-06-28
SI2515889T1 (sl) 2015-04-30
WO2011076367A2 (en) 2011-06-30
NZ599839A (en) 2014-02-28
ZA201202482B (en) 2012-12-27
JP2013515022A (ja) 2013-05-02
AU2010335594B2 (en) 2015-05-21
KR20120107970A (ko) 2012-10-04
DK2515889T3 (en) 2015-03-02
MX2012007166A (es) 2012-07-23
EA201290373A1 (ru) 2012-11-30
CN102652017A (zh) 2012-08-29
WO2011076367A3 (en) 2011-09-01
US10022449B2 (en) 2018-07-17
PT2515889E (pt) 2015-03-20
KR101862415B1 (ko) 2018-05-29
US20120302522A1 (en) 2012-11-29
BR112012015202B1 (pt) 2020-12-08
CA2779532C (en) 2018-05-22
IL219552A (en) 2016-11-30

Similar Documents

Publication Publication Date Title
BR112012015202A2 (pt) "iota - e/ou kappa-carrgenado junto com um inibidor da neuraminidase, método para o tratamento profilático ou terapêutico de um sintoma, condição ou doença, composição farmacêutica,e, kit de partes".
ECSP12011834A (es) Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, métodos para su tratamiento y sus usos.
BR112013022789A2 (pt) composições farmacêuticas que compreendem metformina e um inibidor dpp-4 ou um inibidor sglt-2
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112012007234A2 (pt) combinação farmacêutica compreendendo inibidor de dpp-4 e metformina, bem como seu uso e seu processo de preparação
PH12014501984A1 (en) Pharmaceutical compositions comprising metformin and a dpp-4 inhibitor or a sglt-2 inhibitor
CR20110509A (es) Composicion farmaceutica
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
BR112014024672A8 (pt) Composições farmacêuticas para terapia de combinação
BRPI0908421C1 (pt) solução estável de um composto farmacêutico
UY33370A (es) Composiciones farmacéuticas comprendiendo un fármaco inhibidor de la DPP4 y de la pioglitazona, procedimientos de preparación y utilización
BR112013029256A2 (pt) "combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina".
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
AR058098A1 (es) Derivados de acidos dicarboxilicos y su uso
BR112014007902A2 (pt) composições farmacêuticas compreendendo 40-o-(2-hidróxi)etil-rapamicina
UY32457A (es) Vacuna del virus del dengue inactivado
BR112012005044A2 (pt) composições que compreendem tramadol e celecoxib no tratamento de dor.
BR112015007814A2 (pt) diagnóstico, prevenção e tratamento de doenças da articulação
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
BRPI0820668A2 (pt) Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina
ES2524385R1 (es) Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH
BR102013003570A8 (pt) Composições de plasma rico em plaquetas
TR201004464A2 (tr) Kemik erimesi için formülasyon.
BR112014029597A2 (pt) compostos de cromano

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/12/2010, OBSERVADAS AS CONDICOES LEGAIS.